Provided by Tiger Trade Technology Pte. Ltd.

ABVC BioPharma, Inc.

1.08
-0.0500-4.42%
Post-market: 1.07-0.0100-0.93%18:39 EDT
Volume:41.11K
Turnover:46.13K
Market Cap:27.46M
PE:-2.75
High:1.19
Open:1.11
Low:1.07
Close:1.13
52wk High:5.48
52wk Low:0.6880
Shares:25.42M
Float Shares:20.60M
Volume Ratio:0.72
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.3933
EPS(LYR):-0.3933
ROE:-119.49%
ROA:-31.25%
PB:2.47
PE(LYR):-2.75

Loading ...

Collegium: Strategic AZSTARYS Acquisition Underpins ADHD Franchise Expansion and Supports Buy Rating

TIPRANKS
·
Mar 20

Press Release: Collegium to Acquire AZSTARYS(R) from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory

Dow Jones
·
Mar 19

Press Release: Cingulate Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

Dow Jones
·
Mar 18

ABVC posts FY 2025 net loss of USD 8.4 million (59% increase)

Reuters
·
Mar 04

Abvc Biopharma Says Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon; Reports Material Weakness In Internal Controls Over Financial Reporting For FY25

Benzinga
·
Mar 04

BRIEF-ABVC Biopharma - Quarterly Period Ended September, 2025 Financial Statements Should Not Be Relied Upon

Reuters
·
Mar 04

ABVC Biopharma Inc - Reports Material Weakness in Internal Controls Over Financial Reporting for FY2025 - SEC Filing

THOMSON REUTERS
·
Mar 04

Paris Hilton Shares Her Experience with JORNAY PM and Launches New 'Embrace Your Sparkle' Campaign with Collegium to Empower the ADHD Community

GlobeNewswire
·
Mar 03

I told my boss I need an ADHD coach and his response was unhelpful. Can we fix our working relationship?

Dow Jones
·
Feb 27

Axsome Explores Solriamfetol In Phase 3 CLARITY Trial For MDD Subset

Simply Wall St.
·
Feb 27

Yukiguni Maitake Sets Medium-Term Plan and Outlines FY2026 Q3 Review

TIPRANKS
·
Feb 09

Yukiguni Maitake Sees FY Net Y2.01B

Dow Jones
·
Feb 09

ABVC Biopharma Inc. Announces Date for Upcoming Annual Shareholder Meeting

Reuters
·
Feb 06

Aytu BioPharma reports Q2 EPS ($1.05) vs. 13c last year

TIPRANKS
·
Feb 04

In My Forties I Found Out I Have ADHD -- Maybe You Do Too -- WSJ

Dow Jones
·
Jan 24

ABVC Biopharma Issues Amendment to Recent SEC Filing

Reuters
·
Jan 17

Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference

GlobeNewswire
·
Jan 15

Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

GlobeNewswire
·
Jan 14

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

GlobeNewswire
·
Jan 12

Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD

prnewswire
·
Jan 06